Venetoclax
- PDF / 169,289 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 31 Downloads / 171 Views
1 S
Various toxicities: 3 case reports In a study conducted between April 2016 and February 2019, three patients [ages and sexes not stated] were described, who developed tumour lysis syndrome along with hyperkalaemia, hyperphosphataemia, hypocalcaemia, intraventricular conduction block or arrhythmia during treatment with venetoclax for chronic lymphocytic leukaemia (CLL). The patients, who had CLL, received treatment with venetoclax [routes not state; not all dosages stated]. Subsequently, all three patients developed venetoclax-related complications: one patient developed tumour lysis symdrome and hyperkalaemia. Due to hyperkalaemia, this patient developed non specific intraventricular conduction block and arrhythmia. One patient developed tumour lysis syndrome after initiation of 20mg venetoclax. The remaining one patient developed tumour lysis syndrome and hypocalcemia (with calcium level of
Data Loading...
